This article has Open Peer Review reports available.
Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study
© Brandão and Costa Fuchs; licensee BioMed Central Ltd. 2002
Received: 30 April 2002
Accepted: 8 August 2002
Published: 8 August 2002
In Brazil, it is estimated that between 2.5 and 4.9% of the general population present anti-hepatitis C virus (HCV) antibodies, which corresponds to as many as 3.9 to 7.6 million chronic carriers. Chronic liver disease is associated with HCV infection in 20% to 58% of the Brazilian patients. The objective of this case-control study was to investigate the risk factors for presence of anti-HCV antibody in blood donors in southern Brazil.
One hundred and seventy eight blood donors with two positive ELISA results for anti-HCV were cases, and 356 controls tested negative. A standardized questionnaire was used to collect data concerning demographic and socioeconomic aspects, history of previous hepatitis infection, social and sexual behaviors, and number of donations. Variables were grouped into sets of hierarchical categories. Cases and controls were compared using logistic regression, odds ratios, and 95% confidence intervals. The statistical significance of the associations was assessed through likelihood ratio tests based on a P value < 0.05.
The prevalence of anti-HCV among blood donors was 1.1%. Most of the donors were white and males. In the multivariate analysis, independent predictors of anti-HCV positivity were: intravenous drug use, blood transfusion >10 years earlier, having had two to four sexually transmitted diseases, incarceration, tattooing, sex with a hepatitis B or C virus carrier or with intravenous drug users.
Intravenous drug use, blood transfusion, and tattooing were the main risk factors for anti-HCV positivity among blood donors from southern Brazil, but sexual HCV transmission should also be considered.
The worldwide prevalence of hepatitis C virus infection is estimated by the World Health Organization (WHO) to be approximately 3% – corresponding to 170 million infected persons [1, 2]. In Brazil, WHO estimates suggest that between 2.5 and 4.9% of the general population present anti-HCV antibodies . This corresponds to as many as 3.9 to 7.6 million chronic carriers at risk for developing liver cirrhosis and/or liver cancer. Studies show that among Brazilian patients with chronic liver disease, 20 to 58% are anti-HCV positive , and that in southern Brazil 27% of the patients with hepatocellular carcinoma are anti-HCV positive .
While the search for an effective therapy  and vaccine  continues, prevention and control of HCV infection should be the goals of public health efforts. Preventive strategies aim to reduce the exposure to HCV should be based on blood testing of individuals, screening of blood and blood products, sterilization of reusable equipment, destruction of potentially contaminated disposable instruments, and promotion of barrier methods of contraception to prevent sexually transmitted diseases . To increase the efficacy of these interventions, it is important that the main risk factors for HCV infection in different populations be known. Therefore, the present case-control study was designed to evaluate risk factors in a representative sample of blood donors in southern Brazil.
Study population and design
A sample of blood donors was randomly selected from eight blood centers in Porto Alegre, state of Rio Grande do Sul, Brazil, out of 11 centers available in the city. Three centers were not included due to the small number of donors. The number of blood donors sampled was proportional to the number of donors of each center. A standard predonation interview was conducted at each center to exclude donors potentialy ill or who reported previous hepatitis or jaundice, and drug addiction. Cases were donors with two positive enzyme-linked immunosorbent assay (EIA) results for anti-HCV carried out using the same manufacturers' kits. Controls were blood donors who tested negative for anti-HCV. Two frequency-matched controls were selected next to a case in the same center.
All blood samples were screened for anti-HCV, hepatitis B surface antigen, hepatitis B core antibody, HIV-1, human T-cell lymphotropic virus types 1 and 2, syphilis (Sexually Transmitted Disease Research Laboratory), Trypanosoma cruzi (etiologic agent of Chagas' disease) and alanine aminotransferase (ALT), using licensed assays. Serological testing for HCV was performed according to standard procedures at the eight blood centers. Initial screening was by second-generation EIA and, after January 1996, by third-generation EIA. The type, generation, and manufacturer of tests varied with blood center.
Data were collected between August 1995 and October 1996. We collected information concerning demographic (gender and age) and socioeconomic (education) aspects, parenteral exposure to blood or blood products, social and sexual behavior, occupational exposure, personal history of jaundice or hepatitis or history of these diseases in the donor's family, and signs and symptoms of human immunodeficiency virus infection. All patients agreed to participate and signed a consent form. Research assistants interviewed cases and controls on a private room at each center, using a standardized questionnaire. Because of the sensitive character of some questions, female or male interviewers were assigned according to the gender of the respondent. The pretested instrument, which was identical for cases and controls, included questions concerning detailed history of blood exposure on previous transfusion and occupational hazard (unintentional needle-stick injuries, for instance), intravenous drug use, tattooing, acupuncture, surgery, previous hospitalization and parenteral administration of drugs. Other questions included age at first intercourse, number of sexual partners (risk category was determined separately for men and women according to the median), history of sexually transmitted diseases -STD- (gonorrhea, syphilis, or an open sore), sex with partners who had been intravenous drug users or who had had hepatitis.
Sample size calculation and data analysis
The calculated sample size of 411 donors (137 cases and 274 controls) allowed detection of a 2.0 odds ratio (OR), with an 80% power at a 0.05 significance level (two tailed), and an exposure prevalence ranging from 15 to 50%. The sample size was increased in approximately 30% to allow assessment of less prevalent types of exposure and adjustment for confounding variables on multivariate analyses.
Data entry was checked for consistency and accuracy using the Epi-Info software, version 6.04, and the analysis was conducted using the Statistical Package for the Social Sciences, version 8.0.
Description of the sample
The overall prevalence of anti-HCV was 1.1% (95%IC = 0.3–1.7), corresponding to 711 repeatedly reactive EIA tests out of 66,414 blood donations in all centers in the city of Porto Alegre between August 1995 and October 1996. A representative sample of 178 anti-HCV positive cases and 356 controls were investigated.
Distribution of demographic and socioeconomic characteristics of cases and controls
(n = 178)
(n = 356)
Number of previous donations
Environmental risk factors for HCV seropositivity among blood donors from southern Brazil
(n = 178)
(n = 356)
Lived in shelter/boarding school
Household contact with jaundice or hepatitis
5. 2 (2.1–12.8)
Enrolled in the army
Worked at detention center or prison
Occupational blood exposure
Previous morbidity as risk factor for HCV seropositivity test among blood donors in southern Brazil
(n = 178)
(n = 356)
Time since last blood transfusion (years)
Time since hospital admission for clinical treatment (years)
Time since parenteral drug treatment (years)
Social and sexual behavior
Social and sexual behavior as risk factor for positive HCV test among blood donors from southern Brazil
(n = 178)
(n = 356)
Intravenous drug use
Age of the first sexual intercourse (years)
Number of sexual partners (median)**
Past ten years
Male <5 / Female <2
Male ≥ 6 / Female ≥ 2
Male ≤ 10 / Female ≤ 2
Male ≥ 11 / Female ≥ 3
Number of lifetime sexually transmitted diseases
Sexual intercourse with intravenous drug user
Sexual intercourse with a partner with hepatitis B or C virus
Cases were younger at their first sexual intercourse and had a higher number of lifetime partners than controls. However, these differences did not reach statistical significance after adjustment for confounding factors. Cases were more likely to have had one or more sexually transmitted diseases during life than controls. This resulted in an OR six times higher for presence of anti-HCV. Sexual intercourse with an injection drug user tripled the risk for HCV seropositivity. Of the 178 cases, 7.9% reported having had sexual intercourse with a partner with hepatitis (vs. 3.4% of the controls), which was associated with a 2.7 fold (95% CI 1.0–7.4) increase in the risk for anti-HCV positivity. This association was even more evident in individuals who had a sexual partner with hepatitis B or C. Sexual intercourse with a partner with hepatitis B or C resulted in a 3.7 fold increase in the independent risk for HCV seropositivity.
This case-control study shows that first-time blood donors, as well as 30 to 59 year-old donors and less educated donors were at higher risk for HCV seropositivity. In addition, our results confirm that injection drug use, blood transfusion, incarceration, tattooing, history of sexually transmitted diseases, and sexual intercourse with injection drug users, partners with hepatitis, or carriers of HBV or HCV increase the risk for a positive anti-HCV test. In the study of risk factors associated with the presence of HCV antibodies, the potential for bias must be ruled out. In the present study, the sampling process enabled a representative sample of donors in the city of Porto Alegre to be detected and enrolled. The inclusion of center-matched control donors with a negative HCV test avoided bias related to differences in the recruitment policy and in the anti-HCV test employed in each center. Immunoblot tests and polymerase chain reaction (PCR) or transcription-mediated amplification (TMA) were not adopted as a routine to test blood donors in Brazil. Even though the specificity of currently available EIAs for anti-HCV is high, the positive predictive value is lower in blood donors . Accordingly, we avoided to label the cases as HCV infected, but anti-HCV seropositives.
An attempt was made to minimize recall bias by asking cases and controls to report information about the same period, and by using the same standardized questionnaire. Since most episodes of hepatitis C are free of symptoms, cases were as likely as controls to recall exposures potentially associated with HCV infection.
When interpreting the results of this study, it is meaningful to bear in mind that the eligible donors were in good health and did not represent the general population.
First-time blood donors had twice the risk for presenting a positive HCV test. This association is plausible, since first-time donors have never been screened [10, 11]. The test-seeking behavior for infectious diseases is unlikely as the Brazilian public health care system offers alternative test sites. In addition, first-time blood donors are less likely to report exposure to risk factors for HCV infection. For instance, in the United States, the deferrable risk (defined as estimated prevalence rate for risk behaviors that would have been a basis for donation deferral if reported at the time of the donor screening among first-time donors was 1.6 times greater than among repeated donors . In this study, 26% of all donors presented a history of jaundice, incarceration, injection drug use, and tattooing. These donors should have been excluded in the predonation interview, according to the Brazilian criteria for blood donation .
Concerning demographic variables, the increase in the risk for HCV seropositivity between 30 and 59 years was different to that described for donors in Australia  or the United States [15, 16], where the infection rate declines in persons greater than 50 years old, and similar that described in other region of our country . This pattern of transmission suggests that the risk for HCV infection was greater in the distant past  and reached a decreased risk of infection along generations as consequence of improving sanitary and socioeconomic conditions over time.
Our results show an inverse and statistically significant association between positive HCV testing and schooling – the risk was greater among illiterate donors or donors with little schooling. These socioeconomic factors have been previously described as acting through risk factors such as illicit drug use  or unsafe injection practices .
In terms of environmental exposure, having been incarcerated in a juvenile detention center or prison was the main risk factor, independently associated with a five-fold increase in positive HCV testing. The association between a previous imprisonment and positive HCV testing is a proxy of the true risks. The risk for inmates to be HCV positive has been associated with injection drug use, tattooing and previous incarceration [20–26]. In addition, the possibility of person-to-person HCV transmission through exposure to contaminated blood cannot be dismissed .
Our study shows that exposure to blood was, and still is, the main risk factor for HCV infection. Blood transfusion more than 10 years ago was associated with positive HCV testing, and the association became even stronger after adjustment for confounding factors. The residual risk for transfusion-transmitted hepatitis C infection decreased after Brazilian blood centers adopted anti-HCV screening tests 10 years ago, but it is still higher than in developed countries . As in other studies [10, 11, 17, 29–33], we observed that illegal injection drug use is the dominant mode of HCV transmission, mostly due to sharing of needles or syringes . Approximately 75% of Brazilian injection drug users are HCV seropositive , and 85% of them share needles . In addition, other parenteral exposure, such as tattooing, was independently associated with HCV seropositivity. Tattooing still is not a regulated businesses and, in the past, most of the tattoing occurred at places where contamination were more likely. This potential risk for HCV transmission in blood donors has been previously reported [11, 30]; presumably, non-sterile or non-disposable equipment is the source of transmission . HCV seropositivity was also independently associated with personal history of jaundice; however, jaundice may be a marker of disease, rather than a risk factor. In this study, the prevalence of HCV infection was not associated with employment in a health-related occupation. Although occupational exposure can result in infection, [38, 39] only 8.9% of blood donors were health care workers and 32% did not handle blood samples.
The importance of sexual activity in the transmission of HCV has not been well-established . Nevertheless, studies with blood donors suggest an association between sexual transmission and HCV [10, 11, 17, 31, 40]. This study detected an independent association between sexual behavior and positive anti-HCV test. The results of the logistic regression model show that the number of sexually transmitted diseases during life and sexual intercourse with injection drug users and with HBV or HCV carriers were independent risk factors for anti-HCV positivity. Even though number of sexual partners and sexual orientation were associated in the bivariate analysis, they were not independent of other risk factors such as transfusion and injection drug use by the donor or his/her sexual partner. In South America, the prevalence of HCV infection in heterosexuals attending STD clinics and with no history of injection drug abuse (11.5%) is greater than in North America (6.0%) and Europe (1.9%) . It is speculated that HCV transmission may be facilitated by sexually transmitted diseases [41, 42]. However, there is a possibility that HCV seropositivity associated with sexual intercourse with injection drug users or HBV/ HCV carriers may result from actual sexual transmission of HCV – although it may also result from exposure to unreported parenteral risk factors or from sharing certain personal items, such as toothbrushes or razors, which can result in accidental exposure to the partner's blood [11, 33, 42].
In conclusion, this case-control study confirmed some independent risk factors for anti-HCV positive test described in other studies of blood donors. The hierarchical multivariate analysis identified age, schooling, incarceration, past transfusion, tattooing, intravenous drug use, number of sexually transmitted diseases, sexual intercourse with injection drug users and partners with hepatitis B or C as the main risk factors for HCV seropositivity in the present population of southern Brazilian donors. Some characteristics of sexual behavior were detected as independent risk factors, suggesting that sexual intercourse is an important source of transmission. The identification of groups at risk and the planning of interventions aimed at controlling HCV infection should take these findings into account.
The authors thank Mauro dos Anjos Silva, Gabriela Coral, Letícia Emer, Fernanda Araújo, Karen Lorenz e Richard Magalhães for their assistance with data collection.
- World Health Organization: Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997, 72: 341-344.Google Scholar
- World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hep. 1999, 6: 35-47. 10.1046/j.1365-2893.1999.6120139.x.View ArticleGoogle Scholar
- World Health Organization: Hepatitis C – global prevalence (update). Wkly Epidemiol Rec. 2000, 75: 17-28.Google Scholar
- Fonseca JC: Epidemiologia da infecção pelo vírus da hepatite C no Brasil. Relatório do Grupo de Estudo da Sociedade Brasileira de Hepatologia. Gastroenterologia Endoscopia Digestiva. 1999, 18 (Supl.1): S3-S8.Google Scholar
- Gonçalves CS, Pereira FEK, Gayotto LCC: Hepatocellular carcinoma in Brazil: report of a national survey (Florianópolis, SC, 1995). Rev Inst Med Trop Sao Paulo. 1997, 39: 165-170.View ArticlePubMedGoogle Scholar
- Heathcote J: Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis. 2000, 20: 185-199. 10.1055/s-2000-9941.View ArticlePubMedGoogle Scholar
- Lechmann M, Liang TJ: Vaccine development for hepatitis C. Semin Liver Dis. 2000, 20: 211-226. 10.1055/s-2000-9947.View ArticlePubMedGoogle Scholar
- Victora CG, Huttly S, Fuchs SC, Olinto MT: The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997, 26: 224-227. 10.1093/ije/26.1.224.View ArticlePubMedGoogle Scholar
- Martins RMB, Vanderborght BOM, Rouzere CD, et al: Anti-HCV related to HCV PCR and risk factors analysis in a blood donor population of central Brazil. Rev Inst Med Trop Sao Paulo. 1994, 36: 501-506.View ArticlePubMedGoogle Scholar
- Conry-Cantilena C, VanRaden M, Gibble J, et al: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996, 334: 1691-1696. 10.1056/NEJM199606273342602.View ArticlePubMedGoogle Scholar
- Delage G, Infante-Rivard C, Chiavetta J-A, Willems B, Pi D, Fast M: Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology. 1999, 116: 893-899.View ArticlePubMedGoogle Scholar
- Williams AE, Thomson RA, Schreiber GB, for the Retrovirus Epidemiology Donor Study, et al: Estimates of infectious disease risk factors in US blood donors. JAMA. 1997, 277: 967-972. 10.1001/jama.277.12.967.View ArticlePubMedGoogle Scholar
- Brasil: Ministério da Saúde. Portaria n° de 19 de novembro de. 1993, 131 (Seção 1): 18405-18415. . Diário Oficial da União, Brasília, DF, 2 dez.Google Scholar
- Kaldor JM, Archer GT, Buring ML, et al: Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust. 1992, 157: 227-230.PubMedGoogle Scholar
- Stevens CE, Taylor PE, Pindyck J, et al: Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. JAMA. 1990, 263: 49-53. 10.1001/jama.263.1.49.View ArticlePubMedGoogle Scholar
- Murphy EL, Bryzman S, Williams AE, for the REDS Investigators, et al: Demographics determinants of hepatitis C virus seroprevalence among blood donors. JAMA. 1996, 275: 995-1000. 10.1001/jama.275.13.995.View ArticlePubMedGoogle Scholar
- Patiño-Sarcinelli F, Hyman J, Camacho LAB, Linhares DB, Azevedo JG: Prevalence and risk factors for hepatitis C antibodies in volunteer blood donors in Brazil. Transfusion. 1994, 34: 138-141. 10.1046/j.1537-2995.1994.34294143942.x.View ArticlePubMedGoogle Scholar
- Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000, 20: 1-16. 10.1055/s-2000-9506.View ArticlePubMedGoogle Scholar
- Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, Edelman RT: Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg. 1993, 49: 440-447.PubMedGoogle Scholar
- Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW: Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust. 1997, 166: 127-130.PubMedGoogle Scholar
- Crofts N, Stewart T, Hearne P, Ping X-P, Breschkin AM, Locarnini SA: Spread of blood-borne viruses among Australian prison entrants. BMJ. 1995, 310: 285-288.View ArticlePubMedPubMed CentralGoogle Scholar
- Ford PM, White C, Kaufmann H, et al: Voluntary anonymous linked study of the prevalence of HIV infection and hepatitis C among inmates in a Canadian federal penitentiary for women. Can Med Assoc J. 1995, 153: 1605-1609.Google Scholar
- Hedouin V, Gosset D: Infection with hepatitis C in a prison environment. A prospective study in Loos-lez-Lille, France. Gastroenterol Clin Biol. 1998, 22: 55-58.PubMedGoogle Scholar
- Gore SM, Bird AG, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ: Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours. QJM. 1999, 92: 25-32. 10.1093/qjmed/92.1.25.View ArticlePubMedGoogle Scholar
- Ruiz JD, Molitor F, Sun RK, et al: Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West J Med. 1999, 170: 156-160.PubMedPubMed CentralGoogle Scholar
- Burattini MN, Massad E, Rozman M, Azevedo RS, Carvalho HB: Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000, 34: 431-436.View ArticlePubMedGoogle Scholar
- Bourlière M, Halfon P, Quentin Y, et al: Covert transmission of hepatitis C virus during bloody fisticuffs. Gastroenterology. 2000, 119: 507-511.View ArticlePubMedGoogle Scholar
- Kupek EJ: Residual transfusion risk for hepatitis B and C in southern Brazil. J Viral Hepat. 2001, 8: 78-82. 10.1046/j.1365-2893.2001.00272.x.View ArticlePubMedGoogle Scholar
- Serfaty L, Giral P, Elghouzzi MH, Jullien AM, Poupon R: Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology. 1993, 17: 183-187. 10.1016/0270-9139(93)90074-W.View ArticlePubMedGoogle Scholar
- Neal KR, Jones DA, Killey D, James V: Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent region (UK). Epidemiol Infect. 1994, 112: 595-601.View ArticlePubMedPubMed CentralGoogle Scholar
- Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G: Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors – the role of parenteral and sexual transmission. Scand J Infect Dis. 1995, 27: 99-104.View ArticlePubMedGoogle Scholar
- Soresi M, Mazzola A, Carroccio A, et al: Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. Hepatogastroenterology. 1998, 45: 150-153.PubMedGoogle Scholar
- Murphy EL, Bryzman SM, Glynn AS, et al: Risk factors for hepatitis C virus infection in United States. Hepatology. 2000, 31: 756-762.View ArticlePubMedGoogle Scholar
- Thomas DL, Vlahov D, Solomon L, et al: Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995, 74: 212-220. 10.1097/00005792-199507000-00005.View ArticlePubMedGoogle Scholar
- Carvalho HB, Mesquita F, Massad E, et al: HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 1: 84-92.View ArticleGoogle Scholar
- Mesquita F: Projeto Brasil: aumento do consumo de heroína no Brasil. Encarte do Boletim Epidemiológico – AIDS. 1997, 6: 3-4.Google Scholar
- Waslet A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000, 20: 1-16. 10.1055/s-2000-9506.View ArticleGoogle Scholar
- Lanphear BP, Linnemann CC, Cannon CG, DeRonde MM, Pendy L, Kerley LM: Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994, 15: 745-50.View ArticlePubMedGoogle Scholar
- Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E, Quinn TC: Viral hepatitis in health care personnel at the Johns Hopkins Hospital: the seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med. 1993, 153: 1705-12. 10.1001/archinte.153.14.1705.View ArticlePubMedGoogle Scholar
- Guerrero-Romero JF, Castañeda A, Rodríguez-Morán M: Prevalencia y factores de riesgo asociados a hepatitis "C" en donadores de sangre en el municipio de Durango, México. Salud Publica Mex. 1996, 38: 94-100.PubMedGoogle Scholar
- Shev S, Widell A, Bergström T, Hermodsson S, Lindholm A, Norkrans G: Herpes simplex virus-2 may increase susceptibility of the sexual transmission of hepatitis C. Sex Transm Dis. 1995, 22: 210-216.View ArticlePubMedGoogle Scholar
- Wejstäl R: Sexual transmission. Proceedings of the International Consensus Conference on Hepatitis C; Feb 26–27; Paris, France. 1999Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/2/18/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.